![](/img/cover-not-exists.png)
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Zaman, Khalil, Winterhalder, Ralph, Mamot, Christoph, Hasler-Strub, Ursula, Rochlitz, Christoph, Mueller, Andreas, Berset, Catherine, Wiliders, Hans, Perey, Lucien, Rudolf, Christine Biaggi, Hawle, HaVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2015.03.016
Date:
July, 2015
File:
PDF, 992 KB
english, 2015